CLARIANT enters next phase with GLOBAL BIOENERGIES' renewable isobutene for high-value application
Evry (France), 22 February 2017 - Global Bioenergies (Alternext Paris: ALGBE) announces that, triggered by the successful completion of a first series of tests of its renewable isobutene for a high-value application, Clariant has now ordered a larger batch of renewable isobutene for a second phase of evaluation.
Clariant is a Swiss stock-market listed company with revenues exceeding 5 billion euros in 2015, active in a variety of chemical markets.
In June last year, Global Bioenergies had provided Clariant with a first sample of its renewable isobutene on which Clariant then successfully carried out first chemical tests and analysis.
As a next step, Clariant has now purchased a larger batch of renewable isobutene in order to run more comprehensive tests over several reaction steps as well as functional assays.
Marc Delcourt, CEO of Global Bioenergies comments: "We are pleased to see that Clariant has a concrete vision on how to bring this high-value application of our renewable isobutene into the market. This second phase paves the way for deliveries in commercial scale quantities once the first renewable isobutene commercial plant will be up and running."
About GLOBAL BIOENERGIES
Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performance of its process, operates an industrial pilot, has started operations at its demo plant in Germany, and is preparing its first full-scale plant through a joint venture with Cristal Union, named IBN-One. The company also replicated its achievement to propylene and butadiene, two members of the gaseous olefins family, key molecules at the heart of petrochemical industry. Global Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 - ALGBE).
Should you like to be kept informed, subscribe to our news feed on
www.global-bioenergies.com
Follow us on Twitter: @GlobalBioenergi
Contact
GLOBAL BIOENERGIES
Frédéric PÂQUES
Chief Operations Officer
Phone: +33 (0)1 64 98 20 50
Email: [email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/ccfde6b4-c674-4442-bfb1-0a3fe7a8b9ad


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Washington Post Publisher Will Lewis Steps Down After Layoffs
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 



